Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan® or MabThera®

NCT04268771 is registered in ClinicalTrials.gov with Dr. Reddy's Laboratories Limited as lead sponsor.

NCT NCT04268771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04268771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan® or MabThera®
Lead sponsor
Dr. Reddy's Laboratories Limited
Phase
Phase 3
Overall status
Completed
Start date
April 8, 2020
Completion date
April 20, 2022
Enrollment
140 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis